Blinatumomab Bridge Therapy for Mitigating Chemotoxicity in Children with Acute Lymphoblastic Leukemia
Indian Journal of Hematology and Blood Transfusion, cilt.41, sa.1, ss.151-154, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 41 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.1007/s12288-024-01791-1
- Dergi Adı: Indian Journal of Hematology and Blood Transfusion
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Sayfa Sayıları: ss.151-154
- Anahtar Kelimeler: Children, Blinotumomab, Bridge therapy
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children, and treatment-related toxicity remains high, especially for high-risk patients. Blinatumomab is the bispecific T-cell engager recently approved for relapsed/refractory ALL. Blinatumomab has a non-myelotoxic toxicity profile and causes B-cell depletion. Data on the use of blinatumomab in chemotherapy-induced toxicity is unclear. We report two pediatric patients with pre-B ALL, treated with blinatumomab because of chemotherapy-associated toxicity, with recovery and successful bridging to further chemotherapy. Blinatumomab can be considered in pediatric ALL patients who develop chemotherapy toxicity and whose treatment is delayed.